Phathom Pharmaceuticals I... (PHAT)
Phathom Pharmaceuticals Statistics
Share Statistics
Phathom Pharmaceuticals has 69.64M shares outstanding. The number of shares has increased by 18.97% in one year.
| Shares Outstanding | 69.64M |
| Shares Change (YoY) | 18.97% |
| Shares Change (QoQ) | 1.84% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 38.7M |
| Failed to Deliver (FTD) Shares | 9K |
| FTD / Avg. Volume | 0.74% |
Short Selling Information
The latest short interest is 14.2M, so 20.77% of the outstanding shares have been sold short.
| Short Interest | 14.2M |
| Short % of Shares Out | 20.77% |
| Short % of Float | 40.7% |
| Short Ratio (days to cover) | 14.61 |
Valuation Ratios
The PE ratio is -1.53 and the forward PE ratio is -1.75. Phathom Pharmaceuticals's PEG ratio is -0.04.
| PE Ratio | -1.53 |
| Forward PE | -1.75 |
| PS Ratio | 9.28 |
| Forward PS | 0.4 |
| PB Ratio | -2.02 |
| P/FCF Ratio | -1.92 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Phathom Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.
| Current Ratio | 4.2 |
| Quick Ratio | 4.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -3.85 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $129.4K |
| Profits Per Employee | $-782.96K |
| Employee Count | 427 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 2.49 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -51.48% in the last 52 weeks. The beta is 0.35, so Phathom Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -51.48% |
| 50-Day Moving Average | 5.51 |
| 200-Day Moving Average | 10.63 |
| Relative Strength Index (RSI) | 45.15 |
| Average Volume (20 Days) | 1.21M |
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of 55.25M and earned -334.33M in profits. Earnings per share was -5.29.
| Revenue | 55.25M |
| Gross Profit | 47.28M |
| Operating Income | -277.47M |
| Net Income | -334.33M |
| EBITDA | -261.52M |
| EBIT | -262.32M |
| Earnings Per Share (EPS) | -5.29 |
Balance Sheet
The company has 297.26M in cash and 501K in debt, giving a net cash position of 296.76M.
| Cash & Cash Equivalents | 297.26M |
| Total Debt | 501K |
| Net Cash | 296.76M |
| Retained Earnings | -1.26B |
| Total Assets | 378.32M |
| Working Capital | 274.41M |
Cash Flow
In the last 12 months, operating cash flow was -266.77M and capital expenditures 0, giving a free cash flow of -266.77M.
| Operating Cash Flow | -266.77M |
| Capital Expenditures | 0 |
| Free Cash Flow | -266.77M |
| FCF Per Share | -4.22 |
Margins
Gross margin is 85.57%, with operating and profit margins of -502.18% and -605.09%.
| Gross Margin | 85.57% |
| Operating Margin | -502.18% |
| Pretax Margin | -605.09% |
| Profit Margin | -605.09% |
| EBITDA Margin | -473.33% |
| EBIT Margin | -502.18% |
| FCF Margin | -482.82% |
Dividends & Yields
PHAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PHAT is $26, which is 428.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $26 |
| Price Target Difference | 428.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.64 |
| Piotroski F-Score | 2 |